biology

Sumitomo Pharma

Sumitomo Pharma is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Sumitomo Pharma rather than just read about it. In short: Sumitomo Pharma Company Limited (住友ファーマ株式会社, Sumitomo Fāma Kabushiki-Gaisha) is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas.

Key takeaways

Sumitomo Pharma belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Sumitomo Pharma to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Sumitomo Pharma from memory before moving on to harder problems.

Reference excerpt

Sumitomo Pharma Company Limited (住友ファーマ株式会社, Sumitomo Fāma Kabushiki-Gaisha) is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka.

History The original Dainippon Pharmaceuticals (Dainippon Seiyaku) was established in 1885 by Nagayo Sensai, a graduate of Tekijuku – the first private medical school in Japan established by Ogata Kōan. It was set up as a wholly privately owned company funded by individuals from Tokyo and Osaka, with the government lending it land and buildings. Technical expertise for the enterprise was provided by Shibata Shokei and Nagai Nagayoshi. The company started its operation in the same year with equipment imported from Germany. The main products were tincture and other similar drugs listed in the Japanese Pharmacopoeia. Among them was ephedrine, an anti-asthma drug invented by Nagai. In 1893, however, Nagai left the company and the business started to record operating losses. In 1898 it was acquired by Osaka Seiyaku. The company produced methamphetamine under the brand name Philopon during WWII for the Imperial Japanese military. Years later, Sumitomo Pharmaceuticals was incorporated separately in 1984 as a subsidiary of Sumitomo Chemical. Dainippon and Sumitomo merged on October 1, 2005, to create Dainippon Sumitomo Pharma. As a result, Sumitomo Chemical has maintained a 51%+ ownership in the company since. Operating without a sales foothold in North America, then-Sumitomo Dainippon Pharma acquired NASDAQ-traded Sepracor for $2.6B in 2009, renaming its new stand-alone subsidiary Sunovion in 2010. Under Sunovion management, Sumitomo Dainippon Pharma was able to successfully market its $2B blockbuster drug Latuda in North America, an atypical antipsychotic approved for the treatment of schizophrenia and depressive episodes associated with Bipolar I disorder. In addition to Latuda, Sunovion achieved other notable commercial achievements with marketed drugs such as Lunesta, Aptiom, and Brovana. In September 2016, the Sunovion subsidiary announced it would acquire Cynapsus Therapeutics for approximately $624 million, to expand Sunovion's central nervous system drug portfolio. With the deal, Sunovion would acquire Cynapsus' then-Phase III Parkinson's disease candidate drug Kynmobi, a sublingual formulation of apomorphine. Sumitomo Dainippon Pharma announced a $3B upfront acquisition in September 2019 of five Roivant subsidiaries, including Urovant and Enzyvant. On April 1, 2022, the company was renamed from Sumitomo Dainippon Pharma to Sumitomo Pharma. In October 2022, Sumitomo Pharma announced the acquisition of all outstanding shares in Myovant, a former Roivant subsidiary it was previously a majority owner of, valuing the company at $2.9B. Following the Myovant acquisition in April 2023, Sumitomo Pharma consolidated its US subsidiaries to form Sumitomo Pharma America, Inc., a wholly owned subsidiary biopharmaceutical company focused on "delivering therapeutic and scientific breakthroughs in areas of critical patient needs spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies". On 26 September 2025, Sumitomo Pharma's stock price fell 5.33%, following US President Donald Trump's announcement of fresh tariffs on pharmaceutical products.

Acquisition history The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

References

External links

Sumitomo Pharma Archived 2020-10-29 at the Wayback Machine Sumitomo Pharma Archived 2020-07-01 at the Wayback Machine (in Japanese) Official website (Archive) "Company history books (Shashi)". Shashi Interest Group. April 2016. Wiki collection of bibliographic works on Sumitomo Pharma

Illustrations

Worked examples

Example 1 — a first encounter with Sumitomo Pharma

Start with the simplest possible case. Write down what Sumitomo Pharma claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Sumitomo Pharma before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Sumitomo Pharma ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Sumitomo Pharma

In research: Sumitomo Pharma appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Sumitomo Pharma in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Sumitomo Pharma is common in secondary-school and first-year university syllabi. It links to neighbouring topics Companies based in Osaka, Companies in the Nikkei 225, Companies listed on the Tokyo Stock Exchange, so understanding it makes those chapters shorter.
In everyday life: Look for Sumitomo Pharma outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Sumitomo Pharma” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Sumitomo Pharma in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Sumitomo Pharma means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Sumitomo Pharma out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Sumitomo Pharma in simple terms?

Why does Sumitomo Pharma matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Sumitomo Pharma?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Sumitomo Pharma.